Page 90 - GPD-1-2

Gene & Protein in Disease Diagnosis and treatment of aldosterone-related diseases

https://doi.org/10.25122/jml-2019-0072 simultaneous quantification of aldosterone, renin activity,
and angiotensin II in human plasma. J Chromatogr B Analyt
27. Fenghua L, 2015, Evaluation of two plasma renin and Technol Biomed Life Sci, 1179: 122740.
aldosterone detection methods for screening efficiency of
primary aldosteronism. Chin J Hyperten, 23(2): 150-153. https://doi.org/10.1016/j.jchromb.2021.122740
28. Yangning H, 2019, Comparison of the diagnostic effects 35. Lingli W, 2020, Application status of mineralocorticoid
of chemiluminescence and radioimmunoassay on primary receptor antagonists in refractory hypertension. Adv
aldosteronism. J Third Mil Med Univ, 41: 2080-2086. Cardiovasc Dis, 41(10): 1026–1030.
29. Fengfan Z, 2019, On the consistency of different methods 36. Junfeng X, 2019, Research progress of mineralocorticoid
for detecting aldosterone concentration in blood. Chin J receptor antagonists. Chin J Gerontol, 34(3): 724–727.
Endocrinol Metab, 35(11): 934-938. 37. Ping Z, 2019, Research Progress of Aldosterone Receptor
30. Jing F, 2021, Screening value of urinary aldosterone Antagonists. Vol. 21. United States: Southwest Military
concentration in primary aldosteronism and comparison of Doctor, p.521–524.
mass spectrometry and chemiluminescence detection. J Sun 38. Ying-ying W, 2020, Virtual screening of antagonists for
Yat Sen Univ, 41(4): 563–571. mineralocorticoid receptor. Chin J N Drugs, 29(6): 655–61.
31. Chenfei J, 2021, Advances in the application of liquid 39. Yuan X, Wang X, Li X, et al., 2019, Aldosterone promotes
chromatography-tandem mass spectrometry in the detection of renal interstitial fibrosis via the AIF1/AKT/mTOR signaling
steroid hormones in CAH screening. Int J Lab Med, 42(7): 881–885. pathway. Mol Med Rep, 20(5): 4033–4044.
32. Zi-yun C, 2021, Diagnostic value of liquid chromatography https://doi.org/10.3892/mmr.2019.10680
tandem mass spectrometry in primary aldosteronism. Chin 40. Haitao Z, 2021, Clinical application of new mineralocorticoid
Clin Med, 28(5): 858–863. receptor antagonists. Chin J Nephrol Dial Transplant, 30(5): 449–50.
33. Pilz S, Keppel MH, Trummer C, et al., 2019, Diagnostic 41. Yujie MM, 2016, Nonsteroidal mineralocorticoid receptor
accuracy of the aldosterone-to-active renin ratio for detecting antagonist finerenone. Modern Med Clin, 31(1): 111–115.
primary aldosteronism. J Endocr Soc, 3(9): 1748–1758.
42. Stewart Coats AJ, Shewan L, 2015, Eplerenone’s role in the
https://doi.org/10.1210/js.2019-00145 management of complex cardiovascular disorders. Int J
Cardiol, 200: 1–2.
34. Chen F, Chen Z, Peng Y, et al., 2021, A liquid chromatography-
tandem mass spectrometry (LC-MS/MS)-based assay for https://doi.org/10.1016/j.ijcard.2015.05.128

Volume 1 Issue 2 (2022) 8 https://doi.org/10.36922/gpd.v1i2.136